Becton, Dickinson and Company (NYSE:BDX) Given Consensus Rating of “Hold” by Analysts

Shares of Becton, Dickinson and Company (NYSE:BDX) have received an average rating of “Hold” from the thirteen ratings firms that are covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $207.6364.

Several equities analysts have recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Stifel Nicolaus increased their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Bank of America increased their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $207.16 on Friday. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The stock has a market cap of $59.02 billion, a P/E ratio of 35.53, a P/E/G ratio of 2.29 and a beta of 0.23. The company’s 50 day moving average price is $195.88 and its two-hundred day moving average price is $189.39. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The company had revenue of $5.89 billion for the quarter, compared to analysts’ expectations of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.0%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend was Monday, December 8th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,662 shares of company stock worth $535,246 in the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

Institutional investors and hedge funds have recently made changes to their positions in the business. SOA Wealth Advisors LLC. grew its position in Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the period. Activest Wealth Management boosted its position in Becton, Dickinson and Company by 285.3% in the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 97 shares during the last quarter. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. Bell Investment Advisors Inc increased its position in shares of Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares during the last quarter. Finally, Cornerstone Planning Group LLC lifted its stake in shares of Becton, Dickinson and Company by 463.3% in the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 139 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.